Document:

Exhibit 10.30.2

 

	
   

  	
  *** TEXT
  OMITTED AND SUBMITTED SEPARATELY PURSUANT TO CONFIDENTIAL TREATMENT REQUEST
  UNDER 17 C.F.R. SECTIONS 200.80(b)(4) AND 230.406

  

 

REF :
C2007-034

 

AMENDING
AGREEMENT #1

 

THIS
AMENDING AGREEMENT is effective as of May 26,
2008 (hereinafter referred to as “Effective Date”) and is made:

 

	
  BETWEEN:

  	
   

  	
  HÉMA-QUÉBEC  

  
	
   

  	
   

  	
  4045
  Côte-Vertu Blvd. 

  
	
   

  	
   

  	
  Saint-Laurent
  (Québec) H4R 2W7 

  
	
   

  	
   

  	
  CANADA

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (hereinafter
  referred to as “HQ”)

  
	
   

  	
   

  	
   

  
	
  AND:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  TALECRIS BIOTHERAPEUTICS LTD.  

  
	
   

  	
   

  	
  5800
  Explorer Drive, Suite 300 

  
	
   

  	
   

  	
  Mississauga
  (Ontario) L4W 5K9 

  
	
   

  	
   

  	
  CANADA

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (hereinafter
  referred to as “TALECRIS CANADA”)

  
	
   

  	
   

  	
   

  
	
  AND:

  	
   

  	
   

  
	
   

  	
   

  	
  TALECRIS BIOTHERAPEUTICS INC.  

  
	
   

  	
   

  	
  P.O. Box
  11526  

  
	
   

  	
   

  	
  79
  TW Alexander Drive  

  
	
   

  	
   

  	
  Research
  Triangle Park (North Carolina) 27709  

  
	
   

  	
   

  	
  USA

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (hereinafter
  referred to as “TALECRIS US”)

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (TALECRIS
  US and TALECRIS CANADA are hereinafter collectively referred to as the
  “Supplier”)

  

 

WHEREAS the Parties entered into a
Purchase Agreement for Fractionation Services and Commercial Products made as
of the lst day of April, 2008 (the “Purchase Agreement”);

 

WHEREAS the Parties desire to amend
the Purchase Agreement in order to modify the Testing Services fee and the
price per unit of measure for GamaSTANMC S/D.

 

NOW, THEREFORE, in consideration of the
mutual covenants and premises contained in this Amending Agreement, the Parties
agree as follows:

 

1.  The revised fee for B19 Testing Services
shall be [***] $US per sample
commencing April 1, 2008.

 

***   CONFIDENTIAL TREATMENT REQUESTED

 

 

REF: C2007-034

 

2.   The revised price for GamaSTANMC S/D shall be [***] $US per mL commencing April 1,
2008.

 

Except
as noted above, aall other covenants, terms, and conditions contained in the
Purchase Agreement shall remained unchanged.

 

IN
WITNESS WHEREOF the Parties have caused this Amending Agreement to be executed
by their duly authorized officers, as of the date first written above.

 

	
  HÉMA-QUÉBEC  

  	
  TALECRIS BIOTHERAPEUTICS INC.  

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  BY:

  	
  /s/
  Francine Décary

  	
   

  	
  BY:

  	
  /s/
  Joel Abelson

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  NAME:

  	
  Francine Décary

  	
   

  	
  NAME:

  	
  Joel
  Abelson

  
	
   

  	
  (printed)

  	
   

  	
   

  	
  (printed)

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  TITLE:

  	
  President and Chief Executive Officer 

  	
   

  	
  TITLE:

  	
  Senior Vice-President
  and General Manager

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  DATE:

  	
  June
  20, 2008

  	
   

  	
  DATE:

  	
  June 11, 2008

  
	
   

  	
   

  	
   

  
	
  TALECRIS
  BIOTHERAPEUTICS LTD.

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  BY:

  	
  /s/
  Joel Abelson

  	
   

  	
   

  	
  [SEAL]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  NAME:

  	
  Joel Abelson

  	
   

  	
   

  	
   

  
	
   

  	
  (printed)

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  TITLE:

  	
  Senior Vice-President
  and General Manager

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  DATE:

  	
  June 11, 2008

  	
   

  	
   

  	
   

  

 

***   CONFIDENTIAL TREATMENT
REQUESTEDExhibit 4.8

 

FORM OF GLOBAL ENHANCED INCOME SECURITY

 

THIS SECURITY IS A GLOBAL ENHANCED
INCOME SECURITY (“EIS”) AND IS REGISTERED IN THE NAME OF A DEPOSITORY OR A
NOMINEE OF A DEPOSITORY OR A SUCCESSOR DEPOSITORY. THIS SECURITY IS NOT
EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE
DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE
INDENTURE, AND NO TRANSFER OF THIS SECURITY (OTHER THAN A TRANSFER OF THIS
SECURITY AS A WHOLE BY THE DEPOSITORY TO THE DEPOSITORY OR ANOTHER NOMINEE OF
THE DEPOSITORY) MAY BE REGISTERED EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED
IN THE INDENTURE.

 

UNLESS THIS CERTIFICATE IS
PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A
NEW YORK CORPORATION (“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF
TRANSFER, EXCHANGE, OR PAYMENT AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE
NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED
REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH
OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY
TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON
IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO. HAS AN INTEREST
HEREIN.

 

EACH EIS CONSISTS OF $7.15
PRINCIPAL AMOUNT OF THE 12.0% SENIOR SUBORDINATED NOTES DUE 2016 (THE “NOTES”)
OF B&G FOODS, INC. (THE “COMPANY”) AND ONE SHARE OF CLASS A COMMON STOCK, PAR
VALUE $0.01 PER SHARE, OF THE COMPANY (SUBJECT TO ADJUSTMENT IN CASE OF A STOCK
SPLIT, STOCK DIVIDEND OR RECLASSIFICATION OF THE CLASS A COMMON STOCK). THE CLASS
A COMMON STOCK AND NOTES EVIDENCED BY THIS CERTIFICATE MAY NOT BE TRANSFERRED
OR EXCHANGED SEPARATELY AND MAY BE TRANSFERRED OR EXCHANGED ONLY TOGETHER UNTIL
SEPARATED IN ACCORDANCE WITH THE TERMS OF THIS CERTIFICATE.

 

 

B&G FOODS, INC.

17,391,305
EISs

 

No. 1

 

CUSIP NO.: 05508R 20 5

ISIN: US05508R2058

 

B&G
Foods, Inc., a Delaware corporation (the “Company”) hereby certifies that Cede &
Co., or registered assigns, is the owner of the number of Enhanced Income
Securities (“EISs”) listed on Schedule A hereto.

 

Each
EIS consists of $7.15 principal amount of 12.0% senior subordinated notes due 2016
of the Company (the “Notes”) and one share of Class A Common Stock, par value
$0.01 per share of the Company (the “Class A Common Stock”) (subject to
adjustment in case of a stock split, stock dividend or reclassification of the Class
A Common Stock as reflected on Schedule B hereto). The global Note and global Class
A Common Stock certificate constituting part of this EISs Certificate are each
attached hereto. The terms of the Notes are governed by an Indenture (the “Indenture”)
dated as of October 14, 2004, among the Company, the Guarantors named therein
and The Bank of New York, as trustee (the “Trustee”), and are subject to the
terms and provisions contained therein, to all of which terms and provisions
the holder of this EISs Certificate consents by acceptance hereof. The Company
will furnish to any holder of this EISs Certificate upon written request and
without charge a copy of the Indenture.

 

Upon
the occurrence of a stock split, stock dividend or reclassification of the Class
A Common Stock, the Company will notify in writing the EIS transfer Agent and
DTC of such event and instruct them to reflect the resulting changes on
Schedule B hereof.

 

This
EISs Certificate is not valid unless countersigned and registered by the
Transfer Agent and Registrar.

 

Automatic Separation:

 

Each
EIS will automatically separate into one share of Class A Common Stock (subject
to adjustment in case of a stock split, stock dividend or reclassification of
the Class A Common Stock as reflected on Schedule B hereto) and $7.15 principal
amount of Notes upon the (i) date on which principal on the Notes becomes due
and payable, whether at the stated maturity of the Notes or upon acceleration
thereof, (ii) any exercise by the Company of its right to redeem all or a
portion of the Notes, or (iii) if DTC is unwilling or unable to continue acting
as securities depository with respect to the EISs or ceases to be a registered
clearing agency under the Securities Exchange Act of 1934 and the Company is
unable to find a successor depository.

 

In
addition, upon a notice by the Company of the issuance by the Company of additional
Notes pursuant to the Indenture (“New Notes”) (i) the EISs represented by this
Certificate will be automatically separated into the Class A Common Stock and
the Notes represented hereby, (ii) this Certificate shall be canceled, and (iii)
a new EIS Certificate(s) will be issued to the holder of this Certificate
representing the same number of EISs (“New EISs”). Each New EIS will consist of
one share of Class A Common Stock (subject to adjustment in case of a stock
split, stock dividend or reclassification of the Class A Common Stock as
reflected on Schedule B hereto) and $7.15 principal amount of a combination of
the Notes and New Notes in proportion to the aggregate principal balances
thereof.

 

 

Voluntary Separation:

 

The
registered holder of this Certificate is entitled, at any time and from time to
time, on or after the earlier of (i) November 29, 2004 or (ii) the occurrence
of a Change of Control (as defined in the Indenture), to separate the EISs
represented by this Certificate or any portion thereof for one share of Class A
Common Stock (subject to adjustments in case of stock split, stock dividend or
reclassification of the Class A Common Stock) and $7.15 principal amount of
Notes for each EIS.

 

Recombination:

 

Any
holder of Class A Common Stock and Notes is entitled, at any time to combine
such holder’s Class A Common Stock and Notes to form EISs.

 

[Remainder of Page Intentionally Left Blank]

 

 

Dated: October 14, 2004

 

B&G FOODS, INC.

 

	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  

 

 

Countersigned and
registered:

 

 

THE BANK OF NEW YORK

as
Transfer Agent and Registrar

 

	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  

 

 

Schedule A

 

NUMBER OF EISs

 

The Number of EISs initially
represented by this global EIS certificate is 17,391,305. The following
increases or decreases have been made:

 

	
  Number of EISs

  Prior to Adjustment

  	
   

  	
  Increase in Amount

  of EISs

  	
   

  	
  Decreases in

  Amount of EISs

  	
   

  	
  Signature

  	
   

  	
  Date

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

Schedule B

 

Number of shares of Class A Common
Stock

 

The number of shares of Class
A Common Stock included in each EIS represented by this Certificate is
initially one. The following adjustments have been made:

 

	
  Number of Shares

  of Class A

  Common Stock

  Included in Each

  EISs Prior to

  Adjustment

  	
   

  	
  Event Triggering

  Adjustment

  	
   

  	
  Number of

  Shares of Class

  A Common

  Stock Included

  in Each EISs

  Following

  Adjustment

  	
   

  	
  Signature

  	
   

  	
  Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}]]